

Supplementary Table 1: Adjusted and unadjusted odds ratios (CI) for being in patient-reported outcome/disease activity measure remission in radiographic axSpA patients versus non-radiographic axSpA patients (reference group) at 6, 12 and 24 months after secukinumab initiation.

| | Months | Unadjusted | Adjusted: Age + sex | Adjusted: Age + sex + baseline CRP | Adjusted: Age + sex + previous b/tsDMARDs | Adjusted: Age + sex + time since diagnosis | Adjusted: Age + sex + registry | Adjusted: All* |
|-------------------------------|--------|--------------------------|--------------------------|------------------------------------|---|--|--------------------------------|-------------------|
| | | MODEL1 | MODEL2 | | | | | MODEL3 |
| Pain (≤ 2) | 6 | 1.7 (1.10 ; 2.74) | 1.7 (1.04 ; 2.63) | 1.6 (1.02 ; 2.60) | 1.5 (0.94 ; 2.42) | 1.7 (1.04 ; 2.65) | 1.3 (0.79 ; 2.19) | 1.3 (0.77 ; 2.16) |
| | 12 | 2.1 (1.21 ; 3.56) | 2.0 (1.15 ; 3.45) | 2.0 (1.13 ; 3.42) | 1.8 (1.02 ; 3.16) | 2.0 (1.5 ; 3.50) | 1.5 (0.82 ; 2.76) | 1.5 (0.82 ; 2.81) |
| | 24 | 1.9 (0.85 ; 4.16) | 1.8 (0.78 ; 3.94) | 1.8 (0.79 ; 4.05) | 1.3 (0.54 ; 3.04) | 1.9 (0.83 ; 4.29) | 0.8 (0.31 ; 2.16) | 0.8 (0.30 ; 2.26) |
| Fatigue (≤ 2) | 6 | 1.6 (0.99 ; 2.55) | 1.5 (0.92 ; 2.42) | 1.4 (0.88 ; 2.33) | 1.4 (0.83 ; 2.22) | 1.5 (0.93 ; 2.48) | 1.0 (0.60 ; 1.75) | 1.0 (0.58 ; 1.74) |
| | 12 | 1.7 (0.99 ; 3.03) | 1.6 (0.88 ; 2.86) | 1.5 (0.84 ; 2.75) | 1.4 (0.77 ; 2.55) | 1.7 (0.93 ; 3.04) | 1.0 (0.49 ; 1.87) | 1.0 (0.49 ; 1.92) |
| | 24 | 2.0 (0.78 ; 5.11) | 1.7 (0.66 ; 4.51) | 1.7 (0.66 ; 4.52) | 1.1 (0.41 ; 3.24) | 1.9 (0.72 ; 5.10) | 0.6 (0.18 ; 1.89) | 0.6 (0.17 ; 2.02) |
| PGA (≤ 2) | 6 | 1.6 (1.05 ; 2.58) | 1.5 (0.95 ; 2.93) | 1.5 (0.95 ; 2.38) | 1.3 (0.84 ; 2.15) | 1.5 (0.93 ; 2.35) | 1.1 (0.65 ; 1.79) | 1.0 (0.58 ; 1.64) |
| | 12 | 1.6 (0.97 ; 2.75) | 1.5 (0.90 ; 2.57) | 1.5 (0.88 ; 2.53) | 1.3 (0.77 ; 2.27) | 1.6 (0.92 ; 2.67) | 0.9 (0.52 ; 1.72) | 0.9 (0.49 ; 1.67) |
| | 24 | 2.1 (0.94 ; 4.60) | 1.9 (0.86 ; 4.32) | 1.9 (0.86 ; 4.39) | 1.1 (0.47 ; 2.82) | 2.1 (0.92 ; 4.74) | 0.8 (0.29 ; 2.05) | 0.6 (0.22 ; 1.81) |
| BASDAI (≤ 2) | 6 | 1.8 (1.15 ; 2.75) | 1.6 (1.05 ; 2.55) | 1.6 (1.03 ; 2.52) | 1.5 (0.94 ; 2.33) | 1.6 (1.05 ; 2.57) | 1.1 (0.69 ; 1.84) | 1.1 (0.64 ; 1.74) |
| | 12 | 2.4 (1.37 ; 4.20) | 2.4 (1.34 ; 4.16) | 2.3 (1.31 ; 4.11) | 2.1 (1.17 ; 3.74) | 2.5 (1.40 ; 4.39) | 1.5 (0.76 ; 2.74) | 1.5 (0.77 ; 2.75) |
| | 24 | 2.5 (1.11 ; 5.70) | 2.4 (1.05 ; 5.53) | 2.5 (1.08 ; 5.77) | 1.61 (0.65 ; 4.00) | 2.8 (1.18 ; 6.46) | 1.0 (0.40 ; 2.74) | 1.0 (0.36 ; 2.96) |
| Back pain (BASDAI Q2) (≤ 2) | 6 | 1.4 (0.93 ; 2.15) | 1.3 (0.87 ; 2.06) | 1.3 (0.86 ; 2.03) | 1.3 (0.81 ; 1.93) | 1.3 (0.86 ; 2.04) | 0.9 (0.58 ; 1.48) | 0.9 (0.54 ; 1.39) |
| | 12 | 1.9 (1.10 ; 3.21) | 1.9 (1.08 ; 3.21) | 1.8 (1.06 ; 3.18) | 1.6 (0.93 ; 2.85) | 1.9 (1.12 ; 3.34) | 1.3 (0.71 ; 2.34) | 1.3 (0.69 ; 2.35) |
| | 24 | 1.7 (0.80 ; 3.68) | 1.7 (0.77 ; 3.64) | 1.7 (0.79 ; 3.82) | 1.3 (0.56 ; 2.87) | 1.9 (0.84 ; 4.09) | 0.9 (0.36 ; 2.04) | 0.9 (0.36 ; 2.20) |
| Joint pain (BASDAI Q3) (≤ 2) | 6 | 2.2 (1.45 ; 3.21) | 2.0 (1.31 ; 2.97) | 1.9 (1.29 ; 2.93) | 1.8 (1.16 ; 2.70) | 2.0 (1.32 ; 3.02) | 1.4 (0.86 ; 2.13) | 1.3 (0.81 ; 2.03) |
| | 12 | 1.9 (1.17 ; 3.07) | 1.8 (1.10 ; 2.93) | 1.8 (1.08 ; 2.91) | 1.6 (0.95 ; 2.63) | 1.8 (1.11 ; 2.97) | 1.2 (0.68 ; 2.06) | 1.1 (0.64 ; 1.98) |
| | 24 | 2.9 (1.35 ; 6.16) | 2.6 (1.18 ; 5.55) | 2.7 (1.23 ; 5.91) | 1.8 (0.79 ; 4.17) | 2.9 (1.34 ; 6.49) | 1.1 (0.43 ; 2.70) | 1.1 (0.43 ; 2.94) |
| Stiffness (BASDAI Q5) (≤ 2) | 6 | 1.5 (1.02 ; 2.28) | 1.5 (0.99 ; 2.26) | 1.5 (0.97 ; 2.23) | 1.4 (0.90 ; 2.08) | 1.5 (0.99 ; 2.26) | 1.1 (0.73 ; 1.78) | 1.1 (0.69 ; 1.70) |
| | 12 | 1.5 (0.91 ; 2.43) | 1.5 (0.91 ; 2.46) | 1.5 (0.91 ; 2.45) | 1.4 (0.82 ; 2.24) | 1.5 (0.91 ; 2.48) | 1.2 (0.67 ; 1.98) | 1.1 (0.63 ; 1.90) |
| | 24 | 1.5 (0.70 ; 3.08) | 1.4 (0.67 ; 3.06) | 1.5 (0.71 ; 3.6) | 0.9 (0.39 ; 2.10) | 1.6 (0.74 ; 3.41) | 0.7 (0.28 ; 1.63) | 0.6 (0.23 ; 1.59) |
| BASFI (≤ 2) | 6 | 1.2 (0.74 ; 1.88) | 1.2 (0.74 ; 1.98) | 1.2 (0.74 ; 1.96) | 1.1 (0.69 ; 1.86) | 2.0 (0.73 ; 1.96) | 1.1 (0.63 ; 1.80) | 1.0 (0.59 ; 1.74) |
| | 12 | 1.2 (0.68 ; 2.15) | 1.3 (0.69 ; 2.28) | 1.2 (0.68 ; 2.26) | 1.2 (0.63 ; 2.12) | 1.2 (0.66 ; 2.21) | 1.3 (0.68 ; 2.50) | 1.2 (0.63 ; 2.44) |
| | 24 | 1.1 (0.49 ; 2.63) | 1.0 (0.42 ; 2.49) | 1.1 (0.43 ; 2.60) | 0.8 (0.32 ; 2.05) | 1.2 (0.50 ; 2.87) | 0.7 (0.30 ; 1.95) | 0.8 (0.30 ; 2.26) |
| ASDAS inactive disease (<1.3) | 6 | 1.5 (0.68 ; 3.15) | 1.5 (0.68 ; 3.28) | 1.5 (0.69 ; 3.37) | 1.4 (0.62 ; 3.04) | 1.5 (0.68 ; 3.33) | 1.4 (0.61 ; 3.26) | 1.4 (0.58 ; 3.18) |
| | 12 | 2.3 (0.80 ; 6.61) | 2.1 (0.73 ; 6.25) | 2.1 (0.73 ; 6.26) | 1.9 (0.65 ; 5.63) | 2.2 (0.76 ; 6.55) | 1.8 (0.57 ; 5.52) | 1.9 (0.58 ; 5.97) |
| | 24 | 1.6 (0.44 ; 5.60) | 1.3 (0.36 ; 4.86) | 1.5 (0.38 ; 5.74) | 0.9 (0.22 ; 3.48) | 1.6 (0.42 ; 5.95) | 0.7 (0.17 ; 2.86) | 0.8 (0.15 ; 3.74) |

*Values were adjusted for age, sex, registry, baseline CRP, time from diagnosis to secukinumab initiation and numbers of previous b/tsDMARDs (0/1/≥2). ASDAS, Ankylosing Spondylitis Disease Activity Score; OR, Odds Ratio; CI, confidence interval; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; PGA, Patient's global assessment; b/tsDMARDs, biologic/ targeted synthetic disease modifying antirheumatic drugs; axSpA, axial Spondyloarthritis. Pain, fatigue, PGA, BASDAI and BASFI were scored on a 0–10 integer scale. Significant values are indicated by bold type.

Supplementary Table 2. Changes in patient-reported outcomes and disease activity measures from baseline to 6, 12 and 24 months after secukinumab initiation, including adjusted and unadjusted estimated differences in radiographic versus non-radiographic axSpA patients.

| | Months | Radiographic axSpA | | Non-radiographic axSpA | | Estimated difference (CI) | | | | | | |
|---|--------|-------------------------------|-----|-------------------------------|----|---------------------------|----------------------------|------------------------------------|--|--|--------------------------------|-----------------------|
| | | Median change (IQR) available | N | Median change (IQR) available | N | Unadjusted MODEL1 | Adjusted: Age + sex MODEL2 | Adjusted: Age + sex + baseline CRP | Adjusted: Age + sex + previous b/tsDMARD (y/n) | Adjusted: Age + sex + time since diagnosis | Adjusted: Age + sex + registry | Adjusted: All* MODEL3 |
| Δ Pain (from baseline) | 6 | -3 (-6;-1) | 486 | -2 (-5;0) | 82 | -0.9 (-1.4;-0.4) | -0.9 (-1.4;-0.3) | -0.6 (-1.2;-0.1) | -0.7 (-1.2;-0.2) | -0.8 (-1.4;-0.3) | -0.4 (-0.9;-0.1) | -0.1 (-0.7;0.5) |
| | 12 | -4 (-6;-2) | 323 | -3.5 (-5;-1) | 54 | -0.7 (-1.3;-0.9) | -0.7 (-1.3;-0.1) | -0.4 (-1.1;0.3) | -0.5 (-1.1;0.1) | -0.7 (-1.3;-0.1) | -0.2 (-0.8;0.5) | 0.1 (-0.6;0.8) |
| | 24 | -4 (-6;-2) | 153 | -3 (-4;-1) | 25 | -0.8 (-1.8;0.1) | -0.7 (-1.7;0.2) | -0.7 (-1.7;0.3) | -0.2 (-1.1;0.7) | -0.9 (-1.8;0.1) | 0.4 (-0.5;1.3) | 0.1 (-0.9;1.1) |
| Δ Fatigue (from baseline) | 6 | -3 (-5;0) | 436 | -1.5 (-4;0) | 72 | -1.2 (-1.8;-0.6) | -1.01 (-1.6;-0.4) | -0.9 (-1.6;-0.2) | -0.7 (-1.3;-0.2) | -0.9 (-1.5;-0.3) | -0.1 (-0.7;0.5) | 0.2 (-0.5;0.9) |
| | 12 | -4 (-6;-1) | 290 | -3 (-5;0) | 44 | -0.8 (-1.5;-1.0) | -0.7 (-1.4;0.01) | -0.4 (-1.2;0.4) | -0.5 (-1.2;0.2) | -0.7 (-1.4;0.02) | 0.1 (-0.6;0.9) | 0.3 (-0.5;1.1) |
| | 24 | -4 (-6;-1) | 138 | -1.5 (-4;0) | 18 | -0.7 (-1.8;-0.5) | -0.4 (-1.5;0.8) | -0.3 (-1.6;1.0) | 0.3 (-0.8;1.5) | -0.6 (-1.7;0.6) | 1.3 (-0.2;2.4) | 1.0 (-0.2;2.3) |
| Δ PGA (from baseline) | 6 | -3 (-5;-1) | 487 | -2 (-4;0) | 83 | -0.9 (-1.4;-0.4) | -0.7 (-1.2;-0.2) | -0.6 (-1.2;0.0) | -0.5 (-1;0.1) | -0.7 (-1.2;-0.2) | -0.1 (-0.6;0.4) | 0.2 (-0.4;0.8) |
| | 12 | -4 (-6;-2) | 324 | -3 (-5;-1) | 53 | -0.8 (-1.4;-0.2) | -0.7 (-1.3;-0.1) | -0.3 (1.0;0.4) | -0.4 (-1.0;0.2) | -0.7 (-1.3;-0.1) | -0.2 (-0.8;0.4) | 0.3 (-0.4;0.9) |
| | 24 | -4 (-7;-1) | 154 | -2 (-5.2;-1) | 24 | -1.3 (-2.2;-0.3) | -1.2 (-2.2;-0.3) | -1.1 (-2.1;0.0) | -0.4 (-1.4;0.5) | -1.4 (-2.4;-0.4) | -0.1 (-1.0;0.9) | -0.1 (-1.1;1.0) |
| Δ BASDAI (from baseline) | 6 | -3.1 (-4.9;-0.9) | 525 | -1.7 (-4.1;-0.5) | 91 | -0.9 (-1.3;-0.4) | -0.7 (-1.2;-0.3) | -0.6 (-1.1;-0.1) | -0.5 (-1.0;-0.1) | -0.7 (-1.1;-0.2) | -0.1 (-0.5;0.3) | 0.2 (-0.4;0.7) |
| | 12 | -3.7 (-5.4;-1.6) | 346 | -2.4 (-4.1;-1.2) | 57 | -0.8 (-1.4;-0.3) | -0.8 (-1.3;-0.2) | -0.5 (-1.1;0.1) | -0.5 (-1.0;0.0) | -0.8 (-1.3;-0.2) | -0.1 (-0.7;0.4) | 0.1 (-0.5;0.6) |
| | 24 | -3.7 (-5.5;-1.5) | 170 | -2.6 (-4.5;-1.3) | 25 | -0.6 (-1.5;0.2) | -0.5 (-1.4;0.4) | -0.3 (-1.2;0.6) | -0.2 (-0.7;1.0) | -0.7 (-1.5;0.2) | 0.6 (-0.2;1.4) | 0.6 (-0.3;1.5) |
| Δ Back pain (BASDAI 2) (from baseline) | 6 | -3 (-6;-1) | 525 | -2 (-4;0) | 91 | -0.9 (-1.4;-0.4) | -0.8 (-1.3;-0.2) | -0.5 (-1.1;0.1) | -0.6 (-1.1;-0.1) | -0.7 (-1.3;-0.2) | -0.2 (-0.7;0.3) | 0.2 (-0.4;0.8) |
| | 12 | -4 (-6;-1) | 346 | -2 (-4;-1) | 57 | -1.0 (-1.6;-0.3) | -0.9 (-1.6;-0.3) | -0.6 (-1.2;0.1) | -0.6 (-1.3;-0.04) | -0.9 (-1.5;-0.3) | -0.3 (-0.9;0.4) | 0.1 (-0.6;0.8) |
| | 24 | -4 (-6;-1) | 170 | -3 (-4;-1) | 25 | -0.7 (-1.7;0.3) | -0.6 (-1.6;0.4) | -0.3 (-1.4;0.8) | -0.1 (-0.9;1.1) | -0.8 (-1.8;-0.2) | 0.6 (-0.3;1.6) | 0.6 (-0.5;1.6) |
| Δ Joint pain (BASDAI 3) (from baseline) | 6 | -2 (-5;0) | 525 | -1 (-4;0) | 91 | -1.0 (-1.5;-0.5) | -0.8 (-1.3;-0.3) | -0.7 (-1.3;-0.1) | -0.6 (-1.1;-0.1) | -0.8 (-1.3;-0.2) | -0.2 (-0.7;0.3) | 0.0 (-0.6;0.6) |
| | 12 | -3 (-5;0) | 346 | -3 (-4;-1) | 57 | -0.6 (-1.2;0.0) | -0.5 (-1.1;0.1) | -0.3 (-0.9;0.4) | -0.3 (-0.9;0.4) | -0.6 (-1.2;0.1) | 0.1 (-0.5;0.7) | -0.2 (-0.5;0.8) |
| | 24 | -3 (-5;0) | 170 | -3 (-6;0) | 25 | -1.2 (-2.1;0.2) | -1.0 (-2.0;-0.1) | -0.8 (-1.8;0.2) | -0.3 (-1.2;0.6) | -1.2 (-2.2;-0.2) | 0.3 (-0.6;1.1) | -0.3 (-0.7;1.3) |
| Δ Stiffness (BASDAI 5) (from baseline) | 6 | -3 (-6;-1) | 525 | -2 (-4.5;-1) | 91 | -0.6 (-1.1;-0.1) | -0.5 (-1.1;-0.01) | -0.6 (-1.2;0.0) | -0.4 (-0.9;0.1) | -0.4 (-0.9;0.1) | -0.02 (-0.6;0.5) | -0.1 (-0.5;0.7) |
| | 12 | -4 (-7;-2) | 346 | -3 (-5;-1) | 57 | -0.7 (-1.3;-0.03) | -0.7 (-1.3;-0.05) | -0.4 (-1.1;0.3) | -0.5 (-1.1;0.1) | -0.7 (-1.3;-0.02) | -0.2 (-0.9;0.4) | 0.1 (-0.6;0.8) |
| | 24 | -4 (-6;-2) | 170 | -4 (-6;-2) | 25 | -0.2 (-1.1;0.8) | -0.1 (-1.1;0.8) | 0.1 (-1.0;1.1) | 0.5 (-0.4;1.5) | -0.3 (-1.3;0.7) | 0.9 (-0.1;1.8) | 0.8 (-0.2;1.9) |
| Δ BASFI (from baseline) | 6 | -1.4 (-3.1;-0.1) | 342 | -0.9 (-2.2;0) | 75 | -0.4 (-0.9;0.2) | -0.4 (-0.9;0.2) | -0.4 (-1.0;0.3) | -0.3 (-0.8;0.3) | -0.3 (-0.9;0.3) | -0.3 (-0.8;0.3) | 0.0 (-0.7;0.7) |
| | 12 | -1.7 (-3.5;-0.3) | 211 | -1.3 (-2.5;-0.2) | 47 | 0.2 (-0.4;0.9) | 0.2 (-0.5;0.9) | 0.4 (-0.3;1.2) | 0.4 (-0.3;1.0) | 0.2 (-0.4;0.9) | 0.1 (-0.6;0.8) | 0.4 (-0.3;1.2) |
| | 24 | -2 (-4.1;-0.5) | 104 | -1.1 (-4;-0.4) | 22 | 0.4 (-0.7;1.4) | 0.6 (-0.4;1.7) | 0.6 (-0.5;1.7) | 1.0 (0.0;2.0) | 0.3 (-0.8;1.3) | 0.9 (-0.1;2.1) | 0.8 (-0.3;2.0) |
| Δ ASDAS (from baseline) | 6 | -1.5 (-2.5;-0.6) | 454 | -1 (-1.9;-0.2) | 73 | -0.1 (-0.3;0.1) | -0.7 (-0.3;0.2) | -0.1 (-0.3;0.2) | 0.03 (-0.2;0.2) | -0.5 (-0.3;0.2) | 0.1 (-0.2;0.3) | 0.1 (-0.1;0.4) |
| | 12 | -1.9 (-2.8;-1) | 305 | -1.2 (-2.3;-0.6) | 49 | -0.2 (-0.4;0.1) | -0.2 (-0.4;0.1) | -0.1 (-0.4;0.2) | -0.1 (-0.3;0.2) | -0.2 (-0.4;0.1) | -0.02 (-0.3;0.2) | 0.1 (-0.2;0.3) |
| | 24 | -2 (-2.7;-1) | 153 | -1.4 (-3;-0.6) | 19 | -0.2 (-0.6;0.2) | -0.2 (-0.6;0.3) | -0.02 (-0.5;0.4) | 0.2 (-0.3;0.6) | -0.3 (-0.7;0.2) | 0.2 (-0.2;0.6) | 0.3 (-0.2;0.7) |

*Values were adjusted for age, sex, registry, baseline CRP, time from diagnosis to secukinumab initiation and numbers of previous b/tsDMARDs (0/1/≥2). BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial Spondyloarthritis; b/tsDMARDs, biologic/ targeted synthetic disease modifying antirheumatic drugs; CI, confidence interval. IQR, Interquartile Range; PGA, Patient's global assessment. Pain, fatigue, PGA, BASDAI and BASFI were scored on a 0–10 integer scale. Significant values are indicated by bold type.

Supplementary Table 3. Different adjusted models presenting odds ratios (CI) for being in patient-reported outcome/disease activity measure remission in radiographic axSpA patients versus non-radiographic axSpA patients (reference group) at 6, 12 and 24 months after secukinumab initiation.

| PRO remission | Months | MODEL 3 | Sensitivity model 1 | Sensitivity model 2 |
|-----------------|--------|--|---|---|
| | | Adjustment for age, sex, registry, baseline CRP, time from diagnosis to secukinumab initiation and numbers of previous b/tsDMARDs (0/1/≥2) | Adjustment for age, sex, registry, baseline CRP, time from diagnosis to secukinumab initiation and numbers of previous b/tsDMARDs (0/1/≥2) + Smoking status | Adjustment for age, sex, registry, baseline CRP, time from diagnosis to secukinumab initiation and numbers of previous b/tsDMARDs (0/1/≥2) + HLA-B27 status |
| Pain (≤2) | 6 | 1.3 (0.8 ; 2.2) | 1.3 (0.7 ; 2.1) | 1.5 (0.9 ; 2.6) |
| | 12 | 1.5 (0.8 ; 2.8) | 1.6 (0.8 ; 2.9) | 1.6 (0.8 ; 3.1) |
| | 24 | 0.8 (0.3 ; 2.3) | 0.8 (0.3 ; 2.3) | 0.8 (0.3 ; 2.5) |
| Fatigue (≤2) | 6 | 1.0 (0.6 ; 1.7) | 1.0 (0.6 ; 1.7) | 1.2 (0.7 ; 2.2) |
| | 12 | 1.0 (0.5 ; 1.9) | 1.0 (0.5 ; 1.9) | 1.1 (0.5 ; 2.2) |
| | 24 | 0.6 (0.2 ; 2.0) | 0.8 (0.2 ; 2.9) | 0.6 (0.1 ; 2.3) |
| PGA (≤2) | 6 | 1.0 (0.6 ; 1.6) | 0.9 (0.5 ; 1.6) | 1.1 (0.6 ; 1.9) |
| | 12 | 0.9 (0.5 ; 1.7) | 0.9 (0.5 ; 1.6) | 0.9 (0.5 ; 1.8) |
| | 24 | 0.6 (0.2 ; 1.8) | 0.7 (0.2 ; 2.3) | 0.6 (0.2 ; 1.9) |
| BASDAI (≤2) | 6 | 1.1 (0.6 ; 1.7) | 1.1 (0.6 ; 1.7) | 1.2 (0.7 ; 2.0) |
| | 12 | 1.5 (0.8 ; 2.8) | 1.4 (0.8 ; 2.7) | 1.5 (0.8 ; 3.0) |
| | 24 | 1.0 (0.4 ; 3.0) | 1.1 (0.4 ; 3.4) | 0.9 (0.3 ; 2.9) |
| BASFI (≤2) | 6 | 1.0 (0.6 ; 1.7) | 1.0 (0.6 ; 1.7) | 1.0 (0.6 ; 1.7) |
| | 12 | 1.2 (0.6 ; 2.4) | 1.3 (0.6 ; 2.6) | 1.2 (0.6 ; 2.5) |
| | 24 | 0.8 (0.3 ; 2.3) | 0.8 (0.3 ; 2.3) | 0.7 (0.2 ; 2.1) |
| ASDAS ID (<1.3) | 6 | 1.4 (0.6 ; 3.2) | 1.3 (0.6 ; 3.1) | 1.3 (0.5 ; 3.0) |
| | 12 | 1.9 (0.6 ; 5.9) | 1.8 (0.6 ; 5.9) | 2.2 (0.6 ; 8.3) |
| | 24 | 0.8 (0.2 ; 3.7) | 1.0 (0.2 ; 5.4) | 0.8 (0.1 ; 6.5) |

ASDAS ID, Ankylosing Spondylitis Disease Activity Score inactive disease; CI, confidence interval; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; PGA, Patient's global assessment; b/tsDMARDs, biologic/ targeted synthetic disease modifying antirheumatic drugs; axSpA, axial Spondyloarthritis. Pain, fatigue, PGA, BASDAI and BASFI were scored on a 0–10 integer scale. Significant values are indicated by bold type.